Dr. Li Chen Receives C.C. Tan Award for Diabetes Treatment Innovation
- Hua Medicine's Dr. Li Chen received the C.C. Tan Life Science Industrialization Award for advancing diabetes treatment.
- His development of dorzagliatin represents a novel approach to managing Type 2 diabetes by restoring glucokinase function.
- This achievement highlights China's role in the biotechnology sector and the importance of recognizing global health innovations.
On November 4, 2024, Hua Medicine, a biotechnology company based in Shanghai and San Francisco, announced that its CEO, Dr. Li Chen, received the C.C. Tan Life Science Industrialization Award. This accolade recognizes Dr. Chen's leadership and innovative contributions to diabetes treatment, particularly through the development of dorzagliatin, a unique drug designed to manage Type 2 diabetes effectively. Unlike traditional therapies, dorzagliatin functions by restoring the natural activity of glucokinase, a critical glucose sensor in the body. This innovation is significant as it symbolizes a broader shift in therapeutic approaches to diabetes, marking a potential pathway toward diabetes remission rather than mere symptom management. Furthermore, George Lin, the Chief Strategy Officer at Hua Medicine, emphasized the importance of acknowledging progress made by Chinese biotechnology firms in the context of ongoing global trade and technological tensions. They believe that recognizing these advancements can foster global collaboration in healthcare, enhancing outcomes for chronic disease management. Thus, Hua Medicine stands at the forefront of transforming diabetes care while demonstrating China's growing influence in the global healthcare landscape.